Technology is often accused of taking precedence over humans. At Evolucare, how is the patient considered?
The patient – and moreover the citizen – is at the center of our processes. It cannot be otherwise, since our solutions, which are intended for the health and social care sectors, cover the patient’s entire pathway and not only their in-hospital pathway. That means that Evolucare also addresses associations in the field of disability, as well as nursing homes and long term care facilities. Our software platforms offer a complete view of the pathway, both medical and medico-social, of the person concerned. Today, we have a revenue of 30 million euros and almost 300 employees, compared to a revenue of 7 million euros and a team of 50 people 10 years ago. Our goal for 2021 is to achieve 45 million euros.
How do you explain this progress?
Our market is driven by regulatory reforms: creation of regional hospital groups, obligation to comply with the DMP [personal medical record]… Moreover, everyone’s expectations of the medical community have evolved considerably over the last fifteen years. This is true in terms of ease of exchange with healthcare organizations (such as hospital institutions), in terms of security, and also with regard to communication of information: making appointments online, mobile access to the shared medical record, accessibility of laboratory or imaging results, etc. Communication of health information requires almost constant development of innovative systems. Hence the fundamental importance of research and development.
What role will artificial intelligence play in the design of new solutions?
Evolucare is a company driven by technological innovation. Our teams develop software ranging from institution management to actual clinical applications. We have also created “Evolucare Labs.” It works with the world of academic research to develop new ways to treat patients, in particular for screening and diagnosis. For that matter, we have worked with APHP and Inserm to develop a high-performing, inexpensive solution called “OphtAI.” It is based on an artificial intelligence algorithm hosted in the cloud. Based on a retinal image, it makes it possible to instantly detect three most common eye diseases, namely diabetic retinopathy, glaucoma and AMD. Solutions like this, which make ophthalmologic expertise more accessible, are designed to be part of to a tele-monitoring pathway that promotes the prevention, screening and diagnosis of eye diseases. OphtAI is currently implemented in several countries (France, Germany, Canada, Chile, Mexico, Lebanon, Turkey, etc.) with multiple perspectives of development and use specific to each regulatory environment. The ambition is clear: to become the world leader in artificial intelligence for ophthalmology.
Does this illustrate your international ambitions?
Evolucare is very active in the markets of Africa, the Maghreb and the Middle East, especially in French-speaking countries. We also have subsidiaries in China and Canada, and have developed very solid activity in Latin America. Our current ambition is to expand in Europe. The markets we are looking at in the short term are Germany and Northern Europe.